X

Bristol-Myers Squibb Company (BMY) nnounces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release

Newsdesk: